Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 12/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462312 | 1.00 | ADORA2B (0.45) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1243773 | 0.95 | ADORA2A (0.45) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1243808 | 0.94 | ADORA2A (0.44) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL9885724 | 0.93 | ADORA2B (0.45) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1240971 | 0.92 | ADORA2B (0.41) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1243815 | 0.92 | ADORA2A (0.42) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL13172254 | 0.92 | ADORA2B (0.43) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1243256 | 0.92 | ADORA2B (0.42) | ADORA2BADORA2AADORA1ADORA3KDM4E | |
| SCHEMBL1240892 | 0.92 | ADORA2A (0.44) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1243563 | 0.91 | ADORA2B (0.44) | ADORA2BADORA2AADORA1ADORA3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694074-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | Gilead Sciences, Inc. (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012154340-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| US-20120258974-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | GILEAD SCIENCES, INC. | 2012-10-11 | — | — | US | claimed |
| US-12258303-B2 | Metal salts and uses thereof | INSPIRNA, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240174595-A1 | METAL SALTS AND USES THEREOF | INSPIRNA, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4073025-B1 | METAL SALTS AND USES THEREOF | INSPIRNA INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11878956-B2 | Metal salts and uses thereof | INSPIRNA, INC. (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230095288-A1 | METAL SALTS AND USES THEREOF | INSPIRNA, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11459292-B2 | Metal salts and uses thereof | INSPIRNA, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220041541-A1 | METAL SALTS AND USES THEREOF | RGENIX, INC. | 2022-02-10 | — | — | US | disclosed |
| US-11174220-B2 | Metal salts and uses thereof | INSPIRNA, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-7884100-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | PGXHEALTH, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884100-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | PGXHEALTH, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884100-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | PGXHEALTH, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258974-A1 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS | ADORA2B, ADORA2A, ADRA2B | ADORA2B 1/4885ADORA2A 2/4885ADORA1 5/4885 |
| US-20240174595-A1 | METAL SALTS AND USES THEREOF | SLC30A5, SLC30A7, SLC30A6 | ADORA2B 1425/4885ADORA2A 2253/4885ADORA1 2058/4885 |
| US-11174220-B2 | Metal salts and uses thereof | SLC30A5, SLC30A7, SLC30A6 | ADORA2B 1425/4885ADORA2A 2253/4885ADORA1 2058/4885 |
| US-20220041541-A1 | METAL SALTS AND USES THEREOF | SLC30A5, SLC30A7, SLC30A6 | ADORA2B 1425/4885ADORA2A 2253/4885ADORA1 2058/4885 |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 3/4885 |
| US-12258303-B2 | Metal salts and uses thereof | SLC30A5, SLC30A7, SLC30A6 | ADORA2B 1425/4885ADORA2A 2253/4885ADORA1 2058/4885 |
| US-11459292-B2 | Metal salts and uses thereof | SLC30A5, SLC30A7, SLC30A6 | ADORA2B 1425/4885ADORA2A 2253/4885ADORA1 2058/4885 |
| US-20230095288-A1 | METAL SALTS AND USES THEREOF | SLC30A5, SLC30A7, SLC30A6 | ADORA2B 1425/4885ADORA2A 2253/4885ADORA1 2058/4885 |
| US-11878956-B2 | Metal salts and uses thereof | SLC30A5, SLC30A7, SLC30A6 | ADORA2B 1425/4885ADORA2A 2253/4885ADORA1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.